The UK Kidney Association Clinical Practice Guideline Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease has now been published.
"SGLT-2 inhibitors represent the most significant advance in the management of progressive CKD identified over the last 20 years and the UKKA are now proud to announce national evidence-based guidelines to support their implementation. Clinicians working both in secondary and primary care need to take note of the recommendations made within these guidelines and work together to safely ensure that those individuals who are likely to benefit from this treatment receive them," say Dr Andrew Frankel and Assoc. Prof. William G. Herrington, working group co-chairs.
Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease